Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Feb 10;6(1):57.
doi: 10.1038/s41392-021-00480-z.

Conserved host-pathogen interactions identify novel treatment options in betacoronavirus infections

Soeren Lukassen  1   2 , Roland Eils  3   4   5
Affiliations
Comment

Conserved host-pathogen interactions identify novel treatment options in betacoronavirus infections

Soeren Lukassen et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
a, b Interaction candidate selection approach used by Gordon et al. to identify druggable host factors involved in SARS-CoV-2 infection. The authors first screened for interactors with viral proteins of SARS-CoV-1, SARS-CoV-2, and MERS-CoV (a) and then filtered these through a knockout/-down screen revealing restriction and dependency factors, respectively (b). c Proposed mechanism of action for an ORF9b-mediated disruption of viral dsRNA sensing and IFNβ production. d Mechanism of action of indomethacin and the control drug celecoxib in prostaglandin synthesis
See this image and copyright information in PMC

Comment on

  • Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms.
    Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, Jureka AS, Obernier K, Guo JZ, Batra J, Kaake RM, Weckstein AR, Owens TW, Gupta M, Pourmal S, Titus EW, Cakir M, Soucheray M, McGregor M, Cakir Z, Jang G, O'Meara MJ, Tummino TA, Zhang Z, Foussard H, Rojc A, Zhou Y, Kuchenov D, Hüttenhain R, Xu J, Eckhardt M, Swaney DL, Fabius JM, Ummadi M, Tutuncuoglu B, Rathore U, Modak M, Haas P, Haas KM, Naing ZZC, Pulido EH, Shi Y, Barrio-Hernandez I, Memon D, Petsalaki E, Dunham A, Marrero MC, Burke D, Koh C, Vallet T, Silvas JA, Azumaya CM, Billesbølle C, Brilot AF, Campbell MG, Diallo A, Dickinson MS, Diwanji D, Herrera N, Hoppe N, Kratochvil HT, Liu Y, Merz GE, Moritz M, Nguyen HC, Nowotny C, Puchades C, Rizo AN, Schulze-Gahmen U, Smith AM, Sun M, Young ID, Zhao J, Asarnow D, Biel J, Bowen A, Braxton JR, Chen J, Chio CM, Chio US, Deshpande I, Doan L, Faust B, Flores S, Jin M, Kim K, Lam VL, Li F, Li J, Li YL, Li Y, Liu X, Lo M, Lopez KE, Melo AA, Moss FR 3rd, Nguyen P, Paulino J, Pawar KI, Peters JK, Pospiech TH Jr, Safari M, Sangwan S, Schaefer K, Thomas PV, Thwin AC, Trenker R, Tse E, Tsui TKM, Wang F, Whitis N, Yu Z, Zhang K, Zhang Y, Zhou F, Saltzberg D; QCRG Structural… See abstract for full author list ➔ Gordon DE, et al. Science. 2020 Dec 4;370(6521):eabe9403. doi: 10.1126/science.abe9403. Epub 2020 Oct 15. Science. 2020. PMID: 33060197 Free PMC article.

References

    1. Gordon DE, et al. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science. 2020;22:eabe9403. doi: 10.1126/science.abe9403. - DOI - PMC - PubMed
    1. Gordon DE, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459–468. doi: 10.1038/s41586-020-2286-9. - DOI - PMC - PubMed
    1. Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science370, eabd4570 (2020). - PMC - PubMed
    1. Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science370, eabd4585 (2020). - PMC - PubMed
    1. Monk, P. D. et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. Respir. Med. 10.1016/S2213-2600(20)30511-7 (2020). - PMC - PubMed

Publication types